HRP20120797T1 - Spojevi i postupci za lijeäśenje vaskularne bolesti - Google Patents
Spojevi i postupci za lijeäśenje vaskularne bolesti Download PDFInfo
- Publication number
- HRP20120797T1 HRP20120797T1 HRP20120797AT HRP20120797T HRP20120797T1 HR P20120797 T1 HRP20120797 T1 HR P20120797T1 HR P20120797A T HRP20120797A T HR P20120797AT HR P20120797 T HRP20120797 T HR P20120797T HR P20120797 T1 HRP20120797 T1 HR P20120797T1
- Authority
- HR
- Croatia
- Prior art keywords
- annexin
- variant
- use according
- functional
- functional analog
- Prior art date
Links
- 208000019553 vascular disease Diseases 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 title 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 28
- 102000004121 Annexin A5 Human genes 0.000 claims 24
- 108090000672 Annexin A5 Proteins 0.000 claims 24
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 claims 9
- 102000054215 human ANXA5 Human genes 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 claims 6
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 claims 6
- 206010047141 Vasodilatation Diseases 0.000 claims 4
- 206010000891 acute myocardial infarction Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 210000003038 endothelium Anatomy 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 230000024883 vasodilation Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 206010042957 Systolic hypertension Diseases 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000006492 vascular dysfunction Effects 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Aneksin A5 ili njegov funkcionalni analog ili varijanta za uporabu u liječenju vaskularne disfunkcije povezane s poremećajem vazodilatacije posredovane endotelom, smanjenom aktivnosti endotelne sintaze dušikovog oksida (eNOS), i/ili smanjenom bioraspoloživosti dušikovog oksida (NO), pri čemu funkcionalni analog ili varijanta Aneksina A5 sadrži protein koji je više od 90% identičan humanom Aneksinu A5, SEQ ID NO:1.
2. Uporaba Aneksina A5 ili njegovog funkcionalnog analoga ili varijante u proizvodnji lijeka za uporabu u liječenju vaskularne disfunkcije povezane s poremećajem vazodilatacije posredovane endotelom, smanjenom aktivnosti endotelne sintaze dušikovog oksida (eNOS), i/ili smanjenom bioraspoloživosti dušikovog oksida (NO), pri čemu funkcionalni analog ili varijanta Aneksina A5 sadrži protein koji je više od 90% identičan humanom Aneksinu A5, SEQ ID NO:1.
3. Aneksin A5 ili njegov funkcionalni analog ili varijanta za uporabu za smanjenje ishemijske boli, pri čemu funkcionalni analog ili varijanta Aneksina A5 sadrži protein koji je više od 90% identičan humanom Aneksinu A5, SEQ ID NO:1.
4. Uporaba Aneksina A5 ili njegovog funkcionalnog analoga ili varijante u proizvodnji lijeka za uporabu za smanjenje ishemijske boli, pri čemu funkcionalni analog ili varijanta Aneksina A5 sadrži protein koji je više od 90% identičan humanom Aneksinu A5, SEQ ID NO:1
5. Aneksin A5 ili njegov funkcionalni analog ili varijanta za uporabu prema zahtjevu 1 ili 3, ili za uporabu prema zahtjevu 2 ili 4, za uporabu za smanjenje rizika pojave akutnog infarkta miokarda (eng. AMI).
6. Aneksin A5 ili njegov funkcionalni analog ili varijanta za uporabu prema bilo kojem od zahtjeva 1, 3 ili 5, ili za uporabu prema zahtjevu 2, 4 ili 5, pri čemu bolesnik koji se liječi pati od bolesti izabrane između angine pektoris, ishemijske bolesti srca, periferne arterijske bolesti, sistoličke hipertenzije, migrene, dijabetesa tipa 2 i erektilne disfunkcije.
7. Aneksin A5 ili njegov funkcionalni analog ili varijanta za uporabu u liječenju, prevenciji ili smanjenju rizika pojave vaskularne bolesti koja je povezana s poremećajem vazodilatacije posredovane endotelom, smanjenom aktivnosti eNOS, i/ili smanjenom bioraspoloživosti NO, pri čemu funkcionalni analog ili varijanta Aneksina A5 sadrži protein koji je više od 90% identičan humanom Aneksinu A5, SEQ ID NO:1.
8. Uporaba Aneksina A5 ili njegovog funkcionalnog analoga ili varijante u proizvodnji lijeka za uporabu u liječenju, prevenciji ili smanjenju rizika pojave vaskularne bolesti koja je povezana s poremećajem vazodilatacije posredovane endotelom, smanjenom aktivnosti eNOS, i/ili smanjenom bioraspoloživosti NO, pri čemu funkcionalni analog ili varijanta Aneksina A5 sadrži protein koji je više od 90% identičan humanom Aneksinu A5, SEQ ID NO: 1
9. Aneksin A5 ili njegov funkcionalni analog ili varijanta prema zahtjevu 7, ili za uporabu prema zahtjevu 8, gdje liječenje smanjuje rizik pojave akutnog infarkta miokarda (AMI).
10. Aneksin A5 ili njegov funkcionalni analog ili varijanta za uporabu prema zahtjevu 7 ili 9, ili za uporabu prema zahtjevu 8 ili 9, gdje se vaskularna bolest izabire između angine pektoris, ishemijske bolesti srca, periferne arterijske bolesti, sistoličke hipertenzije, migrene, dijabetesa tipa 2 i erektilne disfunkcije.
11. Aneksin A5 ili njegov funkcionalni analog ili varijanta za uporabu prema bilo kojem od zahtjeva 7, 9 ili 10, ili za uporabu prema bilo kojem od zahtjeva 8 do 10, gdje će se Aneksin A5 ili njegov funkcionalni analog ili varijanta primjenjivati zajedno s trombolitičkim terapijskim sredstvom kao što je aktivator tkivnog plazminogena, urokinaza ili bakterijski enzim.
12. Aneksin A5 ili njegov funkcionalni analog ili varijanta za uporabu prema bilo kojem od zahtjeva 7 ili 9 do 11, ili uporabu prema bilo kojem od zahtjeva 8 do 11, gdje će se Aneksin A5 ili njegov funkcionalni analog ili varijanta primjenjivati zajedno s antitrombotskim sredstvom kao što je klopidogrel ili aspirin.
13. Aneksin A5 ili njegov funkcionalni analog ili varijanta za uporabu prema bilo kojem od zahtjeva 1, 3, 5 do 7, ili 9 do 12, ili uporabu prema bilo kojem od zahtjeva 2, 4 do 6, ili 8 do 12, gdje se Aneksin A5 ili njegov funkcionalni analog ili varijanta izabire između;
a) humanog Aneksina A5 (SEQ ID NO: 1),
b) ortologa humanog Aneksina A5 iz sisavca,
c) alelne ili genetičke varijante od a) ili b),
d) funkcionalnog analoga Aneksina A5 koji je protein koji je više od 95% identičan humanom Aneksinu A5, SEQ ID NO:1,
e) dimera ili fuzijskog proteina koji sadrži bilo što od a), b), c) ili d), i
f) PEGilirane varijante bilo kojeg od a), b), c), d) ili e).
14. Aneksin A5 ili njegov funkcionalni analog ili varijanta za uporabu prema bilo kojem od zahtjeva 1, 3, 5 do 7, ili 9 do 13, ili uporabu prema bilo kojem od zahtjeva 2, 4 do 6, ili 8 do 13, koji će se primjenjivati parenteralno, intravenski, intraarterijski, intra-peritonealno, intramuskularno ili potkožno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1459407P | 2007-12-18 | 2007-12-18 | |
| PCT/GB2008/004195 WO2009077764A1 (en) | 2007-12-18 | 2008-12-18 | Compounds and methods for the treatment of vascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120797T1 true HRP20120797T1 (hr) | 2012-12-31 |
Family
ID=40419062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120797AT HRP20120797T1 (hr) | 2007-12-18 | 2012-10-04 | Spojevi i postupci za lijeäśenje vaskularne bolesti |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8809497B2 (hr) |
| EP (1) | EP2234631B1 (hr) |
| JP (1) | JP2011506590A (hr) |
| KR (1) | KR20100105652A (hr) |
| CN (1) | CN102223892A (hr) |
| AU (1) | AU2008337284B2 (hr) |
| BR (1) | BRPI0821272A2 (hr) |
| CA (1) | CA2708956C (hr) |
| DK (1) | DK2234631T3 (hr) |
| ES (1) | ES2393163T3 (hr) |
| HR (1) | HRP20120797T1 (hr) |
| MX (1) | MX2010006719A (hr) |
| PL (1) | PL2234631T3 (hr) |
| PT (1) | PT2234631E (hr) |
| SI (1) | SI2234631T1 (hr) |
| WO (1) | WO2009077764A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2630013T3 (es) | 2008-02-22 | 2017-08-17 | Annexin Pharmaceuticals Ab | Compuestos y procedimientos para la prevención o tratamiento de reestenosis |
| JP5590621B2 (ja) | 2008-10-17 | 2014-09-17 | ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド | 炎症性障害の処置を処置するためのアネキシンおよびその使用 |
| PL2694538T3 (pl) | 2011-04-05 | 2017-04-28 | Annexin Pharmaceuticals Ab | Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5 |
| PL2668947T3 (pl) * | 2012-05-31 | 2017-06-30 | G. Pohl-Boskamp Gmbh & Co. Kg | Indukcja arteriogenezy donorem NO, takim jak nitrogliceryna |
| GB2542391A (en) | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
| CN111494608A (zh) * | 2020-05-08 | 2020-08-07 | 北京大学第三医院（北京大学第三临床医学院） | 预防或治疗子痫前期及相关病症的药物及其应用 |
| WO2022263407A2 (en) | 2021-06-14 | 2022-12-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2438907A1 (en) | 2001-02-15 | 2002-09-06 | King Pharmaceuticals, Inc. | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
| US7645739B2 (en) * | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
| US20050222030A1 (en) * | 2001-02-21 | 2005-10-06 | Anthony Allison | Modified annexin proteins and methods for preventing thrombosis |
| US7635676B2 (en) * | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
| JP2005526778A (ja) * | 2002-03-15 | 2005-09-08 | アストラル，インコーポレイテッド | 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法 |
| US20040022731A1 (en) * | 2002-04-26 | 2004-02-05 | Alexei Bogdanov | In vivo imaging of apoptosis |
| US7378393B2 (en) * | 2002-06-06 | 2008-05-27 | Tze Chein Wun | Recombinant anticoagulant proteins |
| US20060029668A1 (en) | 2002-10-24 | 2006-02-09 | Ron Eyal S | Sustained release L-arginine formulations and methods of manufacture and use |
| WO2005035001A1 (en) | 2003-09-29 | 2005-04-21 | Enos Pharmaceuticals, Inc. | Sustained release l-arginine formulations and methods of manufacture and use |
| WO2005018436A2 (en) * | 2003-08-26 | 2005-03-03 | The Trustees Of Boston University | Methods for the diagnosis, prognosis and treatment of metabolic syndrome |
| ES2356364T3 (es) * | 2004-04-15 | 2011-04-07 | Athera Biotechnologies Ab | Anexina v para prevenir la ruptura de la placa. |
| WO2005107789A1 (en) * | 2004-04-30 | 2005-11-17 | The Board Of Trustees Of The Leland Stanford Junior University | Use of delta pkc peptides for modulation of reactive oxigen species |
| US7511016B2 (en) * | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| US20090155236A1 (en) * | 2004-08-02 | 2009-06-18 | National Institues Of Health (Nih), U.S. Dept Of Health And Human Service U.S. Government | Peptide sequence for modulation of delta protein kinase c |
| JP4949661B2 (ja) * | 2004-09-21 | 2012-06-13 | 第一三共株式会社 | ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物 |
| TW200612896A (en) * | 2004-09-21 | 2006-05-01 | Sankyo Co | Pharmaceutical compositions containing with HMG-CoA reductase inhibitor and glutathione |
| US7393833B2 (en) * | 2005-03-09 | 2008-07-01 | The Board Of Regents Of The University Of Oklahoma | Chimeric proteins with phosphatidylserine binding domains |
| NZ569078A (en) * | 2005-12-12 | 2012-01-12 | Mosamedix Bv | Annexin derivatives suitable for pretargeting in therapy and diagnosis |
-
2008
- 2008-12-18 PL PL08862538T patent/PL2234631T3/pl unknown
- 2008-12-18 CN CN2008801215145A patent/CN102223892A/zh active Pending
- 2008-12-18 AU AU2008337284A patent/AU2008337284B2/en not_active Ceased
- 2008-12-18 ES ES08862538T patent/ES2393163T3/es active Active
- 2008-12-18 EP EP08862538A patent/EP2234631B1/en active Active
- 2008-12-18 WO PCT/GB2008/004195 patent/WO2009077764A1/en active Application Filing
- 2008-12-18 KR KR1020107014966A patent/KR20100105652A/ko not_active Application Discontinuation
- 2008-12-18 PT PT08862538T patent/PT2234631E/pt unknown
- 2008-12-18 SI SI200830786T patent/SI2234631T1/sl unknown
- 2008-12-18 MX MX2010006719A patent/MX2010006719A/es unknown
- 2008-12-18 CA CA2708956A patent/CA2708956C/en active Active
- 2008-12-18 JP JP2010538896A patent/JP2011506590A/ja active Pending
- 2008-12-18 US US12/808,947 patent/US8809497B2/en active Active
- 2008-12-18 DK DK08862538.9T patent/DK2234631T3/da active
- 2008-12-18 BR BRPI0821272-4A patent/BRPI0821272A2/pt not_active Application Discontinuation
-
2012
- 2012-10-04 HR HRP20120797AT patent/HRP20120797T1/hr unknown
-
2014
- 2014-07-31 US US14/447,782 patent/US9649355B2/en active Active
-
2016
- 2016-05-05 US US15/147,377 patent/US9682122B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2708956C (en) | 2018-07-17 |
| US20100291064A1 (en) | 2010-11-18 |
| PT2234631E (pt) | 2012-11-20 |
| WO2009077764A1 (en) | 2009-06-25 |
| BRPI0821272A2 (pt) | 2015-06-16 |
| ES2393163T3 (es) | 2012-12-19 |
| AU2008337284B2 (en) | 2014-09-18 |
| JP2011506590A (ja) | 2011-03-03 |
| US8809497B2 (en) | 2014-08-19 |
| US20150010531A1 (en) | 2015-01-08 |
| US9649355B2 (en) | 2017-05-16 |
| KR20100105652A (ko) | 2010-09-29 |
| CA2708956A1 (en) | 2009-06-25 |
| US20160235811A1 (en) | 2016-08-18 |
| PL2234631T3 (pl) | 2013-03-29 |
| CN102223892A (zh) | 2011-10-19 |
| EP2234631A1 (en) | 2010-10-06 |
| SI2234631T1 (sl) | 2013-02-28 |
| US9682122B2 (en) | 2017-06-20 |
| EP2234631B1 (en) | 2012-09-12 |
| AU2008337284A1 (en) | 2009-06-25 |
| MX2010006719A (es) | 2010-09-28 |
| DK2234631T3 (da) | 2013-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120797T1 (hr) | Spojevi i postupci za lijeäśenje vaskularne bolesti | |
| JP6229038B2 (ja) | 修飾された血管作動性腸管ペプチド | |
| Chan et al. | Snake venom toxins: toxicity and medicinal applications | |
| WO2002038171A3 (en) | METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2009500045A5 (hr) | ||
| WO2004074486A3 (en) | Fusion proteins of interferon alpha muteins with improved properties | |
| EA200600782A1 (ru) | Терапевтические применения вариантов хемокинов | |
| RU2001132140A (ru) | Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин VI и его применение в фармацевтике | |
| ZA202204624B (en) | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same | |
| EA200601579A1 (ru) | Пептид, повышающий резистентность капилляров, фармацевтическая композиция на его основе и способ ее применения | |
| JP2002530353A5 (hr) | ||
| JP2012524725A5 (hr) | ||
| WO2006029487A8 (en) | Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis | |
| Wang et al. | Platelet microvesicles promote the recovery of neurological function in mouse model of cerebral infarction by inducing angiogenesis | |
| IL163091A (en) | Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction | |
| MX2022008748A (es) | Administración oral de péptidos. | |
| KR960701649A (ko) | Xa인자 억제활성을 가진 신규 폴리펩티드 | |
| EP1902725A3 (en) | Revascularization of ischemic retinal tissue | |
| DE602004025328D1 (de) | Hypoxie-induzierbares vegf plasmid für ischämische erkrankung | |
| JP2002529515A5 (hr) | ||
| US8318660B2 (en) | Method of treating a disease by administering caspase-8 | |
| JP2019524089A5 (hr) | ||
| HUP0301119A2 (hu) | Bioaktiváló hatóanyag és gyógyszerkészítmény | |
| WO2002098454A3 (en) | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |